We feel now is a pretty good time to analyse Amylyx Pharmaceuticals, Inc.'s ( NASDAQ:AMLX ) business as it appears the company may be on the cusp of a considerable accomplishment. Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's loss has recently broadened since it announced a US$88m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$184m, moving it further away from breakeven. Many investors are wondering about the rate at which Amylyx Pharmaceuticals will turn a profit, with the big question being "when will the company breakeven?" We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.